Cannabinoid Receptor 1 Gene Polymorphisms and Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome and in Healthy Controls

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Kuliczkowska Plaksej, Justyna ^a   Laczmanski, Lukasz ^a   Milewicz, Andrzej ^a   Lenarcik Kabza, A ^a   Trzmiel Bira, Anna ^a   Zaleska Dorobisz, Urszula ^a   Lwow, Felicja ^b   Hirnle, Lidia ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY SCHOOL OF PHYSICAL EDUCATION   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; GENOMIC DNA;

ADULT; ARTICLE; CANNABINOID 1 RECEPTOR GENE; CASE CONTROL STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ECHOGRAPHY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; MULTIPLEX POLYMERASE CHAIN REACTION; NONALCOHOLIC FATTY LIVER; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84935018657     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/232975     Document Type: Article

References (60)

1. E. Diamanti-Kandarakis and A. G. Papavassiliou, "Molecular mechanisms of insulin resistance in polycystic ovary syndrome," Trends in Molecular Medicine, Vol. 12, no. 7, pp. 324-332, 2006.
2. F. Álvarez-Blasco, J. I. Botella-Carretero, J. L. San Millán, and H. F. Escobar-Morreale, "Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women," Archives of Internal Medicine, Vol. 166, no. 19, pp. 2081-2086, 2006.
3. H. Teede, A. Deeks, and L. Moran, "Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan," BMC Medicine, Vol. 8, article 41, 2010.
4. G. Vernon, A. Baranova, and Z. M. Younossi, "Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults," Alimentary Pharmacology and Therapeutics, Vol. 34, no. 3, pp. 274-285, 2011.
5. A. Baranova, T. P. Tran, A. Birerdinc, and Z. M. Younossi, "Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease," Alimentary Pharmacology and Therapeutics, Vol. 33, no. 7, pp. 801-814, 2011.
6. P. Angulo, "Nonalcoholic fatty liver disease," The New England Journal of Medicine, Vol. 346, pp. 1221-1231, 2002.
7. M. M. Brzozowska, G. Ostapowicz, and M. D. Weltman, "An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome," Journal of Gastroenterology and Hepatology, Vol. 24, no. 2, pp. 243-247, 2009.
8. C. H. Kim and Z. M. Younossi, "Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome," Cleveland Clinic Journal of Medicine, Vol. 75, no. 10, pp. 721-728, 2008.
9. L. F. N. Zueff, W. P. Martins, C. S. Vieira, and R. A. Ferriani, "Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome," Ultrasound in Obstetrics and Gynecology, Vol. 39, no. 3, pp. 341-347, 2012.
10. N. Hossain, M. Stepanova, A. Afendy et al., "Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS)," Scandinavian Journal of Gastroenterology, Vol. 46, no. 4, pp. 479-484, 2011.
11. I. R. Dinu, S. G. Popa, M. Moţa et al., "The association of the rs1049353 polymorphism of the CNR1 gene with hypoad-iponectinemia," Romanian Journal of Morphology and Embryology, Vol. 52, no. 3, pp. 791-795, 2011.
12. D. Osei-Hyiaman, M. DePetrillo, P. Pacher et al., "Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity," Journal of Clinical Investigation, Vol. 115, no. 5, pp. 1298-1305, 2005.
13. K. M. Starowicz, L. Cristino, I. Matias et al., "Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet," Obesity, Vol. 16, no. 3, pp. 553-565, 2008.
14. I. R. Dinu, S. Popa, M. Bîcu, E. Moţa, and M. Moţa, "The implication of CNR1 gene's polymorphisms in the modulation of endocannabinoid system effects," Romanian Journal of Internal Medicine, Vol. 47, no. 1, pp. 9-18, 2009.
15. K. Eckardt, H. Sell, A. Taube et al., "Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle," Diabetologia, Vol. 52, no. 4, pp. 664-674, 2009.
16. A. Mallat and S. Lotersztajn, "Endocannabinoids and Liver Disease. I. Endocannabinoids and their receptors in the liver," American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 294, no. 1, pp. G9-G12, 2007.
17. 1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe study," European Heart Journal, Vol. 29, no. 14, pp. 1761-1771, 2008.
18. J. P. Després, A. Golay, and L. Sjöström, "Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia," The New England Journal of Medicine, Vol. 353, no. 20, pp. 2121-2134, 2005.
19. F. X. Pi-Sunyer, L. J. Aronne, H. M. Heshmati, J. Devin, and J. Rosenstock, "Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial," Journal of the American Medical Association, Vol. 295, no. 7, pp. 761-775, 2006.
20. A. J. Scheen, N. Finer, P. Hollander, M. D. Jensen, and L. F. van Gaal, "Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study," The Lancet, Vol. 368, no. 9548, pp. 1660-1672, 2006.
21. J. Rosenstock, P. Hollander, S. Chevalier, and A. Iranmanesh, "SERENADE: the study evaluating rimonabant efficacy in drugnaive diabetic patients: effects of monotherapy with rimonabant, the first selective CB 1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes," Diabetes Care, Vol. 31, no. 11, pp. 2169-2176, 2008.
22. W. Jeong, D. Osei-Hyiaman, O. Park et al., "Paracrine activation of hepatic cb1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver," Cell Metabolism, Vol. 7, no. 3, pp. 227-235, 2008.
23. F. Teixeira-Clerc, B. Julien, P. Grenard et al., "CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis," Nature Medicine, Vol. 12, no. 6, pp. 671-676, 2006.
24. W. I. Jeong, D. Osei-Hyiaman, O. Park et al., "Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver," Cell Metabolism, Vol. 7, no. 3, pp. 227-235, 2008.
25. P. Gazzerro, M. G. Caruso, M. Notarnicola et al., "Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population," International Journal of Obesity, Vol. 31, no. 6, pp. 908-912, 2007.
26. D. Osei-Hyiaman, J. Liu, L. Zhou et al., "Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice," Journal of Clinical Investigation, Vol. 118, no. 9, pp. 3160-3169, 2008.
27. M. Gary-Bobo, G. Elachouri, J. F. Gallas et al., "Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese zucker fa/fa rats," Hepatology, Vol. 46, no. 1, pp. 122-129, 2007.
28. J. Westerbacka, A. Kotronen, B. A. Fielding et al., "Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease," Gastroenterology, Vol. 139, no. 6, pp. 1961-1971, 2010.
29. C. Hézode, E. S. Zafrani, F. Roudot-Thoraval et al., "Daily cannabis Use: a novel risk factor of steatosis severity in patients with chronic hepatitis C," Gastroenterology, Vol. 134, no. 2, pp. 432-439, 2008.
30. K. A. Alswat, "The role of endocannabinoids system in fatty liver disease and therapeutic potentials," Saudi Journal of Gastroenterology, Vol. 19, no. 4, pp. 144-151, 2013.
31. M. R. El-Talatini, A. H. Taylor, J. C. Elson, L. Brown, A. C. Davidson, and J. C. Konje, "Localisation and function of the endocannabinoid system in the human ovary," PLoS ONE, Vol. 4, no. 2, Article ID e4579, 2009.
32. A. M. Di Blasio, M. Vignali, and D. Gentilini, "The endocannabinoid pathway and the female reproductive organs," Journal of Molecular Endocrinology, Vol. 50, no. 1, pp. R1-R9, 2012.
33. M. R. El-Talatini, J. C. Elson, A. H. Taylor, and J. C. Konje, "The endocannabinoid, anandamide, is involved in human folliculogenesis and oocyte maturation during IVF treatment," in Proceedings of the 2nd SGI International Summit in Reproductive Medicine - From Embryo and Endometrium to Implantation, p. 59, Valencia, Spain, 2007.
34. L. L. Murphy, R. W. Steger, M. S. Smith, and A. Bartke, "Effects of delta-9-tetrahydrocannabinol, cannabinol and cannabidiol, alone and in combinations, on luteinizing hormone and prolactin release and on hypothalamic neurotransmitters in the male rat," Neuroendocrinology, Vol. 52, no. 4, pp. 316-321, 1990.
35. I. Matias, M. Gonthier, P. Orlando et al., "Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia," Journal of Clinical Endocrinology and Metabolism, Vol. 91, no. 8, pp. 3171-3180, 2006.
36. F. J. Bermúdez-Silva, J. Suárez, E. Baixeras et al., "Presence of functional cannabinoid receptors in human endocrine pancreas," Diabetologia, Vol. 51, no. 3, pp. 476-487, 2008.
37. F. J. Bermúdez-Silva, J. Suárez Pérez, A. Nadal, and F. Rodríguez de Fonseca, "The role of the pancreatic endocannabinoid system in glucose metabolism," Best Practice & Research Clinical Endocrinology & Metabolism, Vol. 23, pp. 87-102, 2009.
38. W. Kim, M. E. Doyle, Z. Liu et al., "Cannabinoids inhibit insulin receptor signaling in pancreatic β-cells," Diabetes, Vol. 60, no. 4, pp. 1198-1209, 2011.
39. R. Pasquali, L. Patton, and A. Gambineri, "Obesity and infertility," Current Opinion in Endocrinology, Diabetes and Obesity, Vol. 14, no. 6, pp. 482-487, 2007.
40. R. Pasquali, A. Gambineri, and U. Pagotto, "The impact of obesity on reproduction in women with polycystic ovary syndrome," BJOG: An International Journal of Obstetrics and Gynaecology, Vol. 113, no. 10, pp. 1148-1159, 2006.
41. N. Battista, N. Pasquariello, M. di Tommaso, and M. Maccarrone, "Interplay between endocannabinoids, steroids and cytokines in the control of human reproduction," Journal of Neuroendocrinology, Vol. 20, no. 1, pp. 82-89, 2008.
42. S. H. Saverymuttu, A. E. A. Joseph, and J. D. Maxwell, "Ultrasound scanning in the detection of hepatic fibrosis and steatosis," British Medical Journal, Vol. 292, no. 6512, pp. 13-15, 1986.
43. X. Ma, N. S. Holalkere, R. A. Kambadakone, M. Mino-Kenudson, P. F. Hahn, and D. V. Sahani, "Imaging-based quantification of hepatic fat: methods and clinical applications," Radiographics, Vol. 29, no. 5, pp. 1253-1277, 2009.
44. A. J. Brown, D. A. Tendler, R. G. McMurray, and T. L. Setji, "Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: beneficial effect of modest weight loss and exercise on liver biopsy findings," Endocrine Practice, Vol. 11, no. 5, pp. 319-324, 2005.
45. M. Gambarin-Gelwan, S. V. Kinkhabwala, T. D. Schiano, C. Bodian, H. Yeh, and W. Futterweit, "Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome," Clinical Gastroenterology and Hepatology, Vol. 5, no. 4, pp. 496-501, 2007.
46. H. Jones, V. S. Sprung, C. J. A. Pugh et al., "Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance," Journal of Clinical Endocrinology and Metabolism, Vol. 97, no. 10, pp. 3709-3716, 2012.
47. A. Markou, I. I. Androulakis, C. Mourmouris et al., "Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome," Fertility and Sterility, Vol. 93, no. 4, pp. 1220-1226, 2010.
48. D. A. de Luis, M. González Sagrado, R. Aller, O. Izaola, R. Conde, and E. Romero, "G1359A polymorphism of the cannabinoid receptor gene (CNR1) and insulin resistance in patients with diabetes mellitus type 2," Nutricion Hospitalaria, Vol. 25, no. 1, pp. 34-38, 2010.
49. D. A. de Luis, M. González Sagrado, R. Aller, O. Izaola, and R. Conde, "Influence of G1359A polymorphism of the cannabinoid receptor gene on anthropometric parameters and insulin resistance in women with obesity," Metabolism: Clinical and Experimental, Vol. 60, no. 2, pp. 272-276, 2011.
50. A. Peeters, S. Beckers, I. Mertens, W. van Hul, and L. van Gaal, "The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men," Endocrine, Vol. 31, no. 2, pp. 138-141, 2007.
51. M. Frost, T. L. Nielsen, K. Wraae et al., "Polymorphisms in the endocannabinoid receptor 1 in relation to fat mass distribution," European Journal of Endocrinology, Vol. 163, no. 3, pp. 407-412, 2010.
52. W. Lieb, A. K. Manning, J. C. Florez et al., "Variants in the CNR1 and the FAAH genes and adiposity traits in the community," Obesity, Vol. 17, no. 4, pp. 755-760, 2009.
53. T. D. Müller, K. Reichwald, A. Wermter et al., "No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents," Molecular Genetics and Metabolism, Vol. 90, no. 4, pp. 429-434, 2007.
54. E. Völgyi, F. A. Tylavsky, A. Lyytikäinen, H. Suominen, M. Alén, and S. Cheng, "Assessing body composition with DXA and bioimpedance: effects of obesity, physical activity, and age," Obesity, Vol. 16, no. 3, pp. 700-705, 2008.
55. M. Benzinou, J. Chèvre, K. J. Ward et al., "Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations," Human Molecular Genetics, Vol. 17, no. 13, pp. 1916-1921, 2008.
56. M. Zhuang, Y. Yang, F. Cao et al., "Associations of variants of CNR1 with obesity and obesity-related traits in Chinese women," Gene, Vol. 495, no. 2, pp. 194-198, 2012.
57. P. Russo, P. Strazzullo, F. P. Cappuccio et al., "Geneticvariations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men," Journal of Clinical Endocrinology and Metabolism, Vol. 92, no. 6, pp. 2382-2386, 2007.
58. D. Schleinitz, S. Carmienke, Y. Böttcher et al., "Role of genetic variation in the cannabinoid type 1 receptor gene (CNR1) in the pathophysiology of human obesity," Pharmacogenomics, Vol. 11, no. 5, pp. 693-702, 2010.
59. A. Milewicz, U. Tworowska-Bardzińska, D. Jedrzejuk et al., "Are endocannabinoid type 1 receptor gene (CNR1) polymorphisms associated with obesity and metabolic syndrome in postmenopausal Polish women?" International Journal of Obesity, Vol. 35, no. 3, pp. 373-377, 2011.
60. Ł. Łaczmański, A. Milewicz, K. Dunajska, D. Jedrzejczuk, M. Pawlak, and F. Lwow, "Endocannabinoid type 1 receptor gene (CNR1) polymorphisms (rs806381, rs10485170, rs6454674, rs2023239) and cardiovascular risk factors in postmenopausal women," Gynecological Endocrinology, Vol. 27, no. 12, pp. 1023-1027, 2011.